These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18856023)

  • 21. Is the increase in osteoporosis prevention a result of the audit?
    Naunton M
    Clin Neurol Neurosurg; 2006 Oct; 108(7):718-9. PubMed ID: 16621242
    [No Abstract]   [Full Text] [Related]  

  • 22. [Risedronate for treatment of osteoporosis].
    Hagino H
    Nihon Rinsho; 2009 May; 67(5):948-53. PubMed ID: 19432115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
    Giljević Z; Vlak T
    Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
    Barrera BA; Wilton L; Harris S; Shakir SA
    Osteoporos Int; 2005 Dec; 16(12):1989-98. PubMed ID: 16133643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R; Camm J; McClung M
    N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and compliance with risedronate in clinical practice.
    Hamilton B; McCoy K; Taggart H
    Osteoporos Int; 2003 May; 14(3):259-62. PubMed ID: 12730745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoporosis in men.
    Lems WF; Geusens PP
    N Engl J Med; 2008 Aug; 359(8):868; author reply 869. PubMed ID: 18724402
    [No Abstract]   [Full Text] [Related]  

  • 32. When do bisphosphonates make the most sense?
    Winzenberg T; Jones G
    J Fam Pract; 2011 Jan; 60(1):18-28. PubMed ID: 21209974
    [No Abstract]   [Full Text] [Related]  

  • 33. Risedronate induced transient ocular myasthenia.
    Raja V; Sandanshiv P; Neugebauer M
    J Postgrad Med; 2007; 53(4):274-5. PubMed ID: 18097124
    [No Abstract]   [Full Text] [Related]  

  • 34. [Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
    Nakayama H
    Clin Calcium; 2007 Oct; 17(10):1607-12. PubMed ID: 17906416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.
    Aurich-Barrera B; Wilton L; Harris S; Shakir SA
    Drug Saf; 2006; 29(2):151-60. PubMed ID: 16454542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 37. [Osteoporosis treatment: choices and options].
    Reginster JY
    Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
    Takada J; Iba K; Imoto K; Yamashita T
    J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risedronate-induced arthritis.
    Yemisci OU; Yalbuzdag SA; Karatas M
    J Clin Rheumatol; 2010 Jun; 16(4):168-9. PubMed ID: 20414126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.